作者
Gopinath S. Palanisamy,Susanna A. Barratt,Chelsea L. Hope,Srinivasan Jayaraman,Brandon Robello,Guadalupe Peña,Raymond A. Ng,David C. Myles
摘要
Histone lysine acetyltransferases KAT6A and KAT6B are frequently dysregulated in cancer and are mechanistically linked to key oncogenic processes. Small-molecule inhibitors of KAT6 have shown promising clinical efficacy, particularly in ER/HER2- metastatic breast cancer. However, KAT6 inhibitors remain largely unexplored in other solid tumors despite strong biological and mechanistic rationale for KAT6 as a potential target. Here, we report for the first time that the inhibition of KAT6 using OP-3136, a highly selective KAT6 inhibitor currently in Phase 1 clinical trials, demonstrates robust anti-tumor activity in preclinical models of prostate cancer, ovarian cancer, and non-small cell lung cancer (NSCLC), both in vitro and in vivo. In vitro proliferation assays were conducted on KAT6A-expressing or overexpressing cell lines: VCAP (prostate cancer), OAW28 (ovarian cancer, KAT6A-amplified), OVCAR3 (ovarian cancer), and LCLC-97TM1 (NSCLC). In vivo efficacy was evaluated in xenograft models using OVCAR3 and LCLC-97TM1 cells in immunocompromised mice.OP-3136 inhibited proliferation across all tested prostate cancer, ovarian cancer and NSCLC cell lines. In the OVCAR3 xenograft ovarian cancer model, oral administration of OP-3136 as monotherapy at 0.5 and 1 mg/kg resulted in tumor regression with tumor growth inhibition (TGI) of 104.5% and 105.4%, respectively. In the LCLC-97TM1 NSCLC xenograft model, monotherapy with OP-3136 at 1 mg/kg achieved a TGI of 62%. These findings highlight the potential of OP-3136 monotherapy to treat prostate, ovarian, and NSCLC tumors and strongly support expanding the clinical investigation of KAT6 inhibitors beyond ER+/HER2- breast cancer. Citation Format: Gopinath S. Palanisamy, Susanna A. Barratt, Chelsea Hope, Srinivasan Jayaraman, Brandon Robello, Guadalupe Peña, Raymond A. Ng, David C. Myles. OP-3136, a selective KAT6 inhibitor, demonstrates anti-tumor activity in prostate, ovarian, and non-small cell lung cancer preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB166.